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ABSTRACT
Donor leukocyte infusions (DLI) are frequently required following reduced intensity conditioned (RIC)
allografts to convert mixed chimerism (MC) to full donor chimerism (FDC). The rationale is to break tolerance
and maximize the graft-versus-leukemia responses. We analyzed the impact of chimerism in 125 recipients of
RIC (Alemtuzumab containing) transplants. Four patterns of chimerism were seen: (1) always 100% donor
chimerism (54%), (2) persisting MC (22%), (3) MC with subsequent development of FDC (18%), (4) lost donor
chimerism (6%). Forty-five (36%) patients received DLI. Chimerism patterns and pre-DLI lymphocyte counts
(pDLI[Ly]) were significantly associated with DLI responsiveness. Complete disease responses were seen in 6
of 17 (35%) group A patients, 9 of 10 (90%) group C patients, and 0 of 6 group B patients (P .027), supporting
reports that chimerism response is a surrogate marker for disease response. In those with MC, pDLI(Ly) were
significantly lower in DLI responsive than nonresponsive patients (P  .044). At 2 years, group C patients had
a significant survival advantage (P  .009) compared to all other groups. In conclusion, the chimerism pattern
was the best indicator of improved survival in this cohort (ie, MC later converting to FDC). In those with MC,
response to DLI therapy was associated with a low lymphocyte count pre-DLI.
© 2007 American Society for Blood and Marrow Transplantation
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dNTRODUCTION
Hematopoietic stem cell transplantation is a well-
ecognized treatment for patients with a variety of he-
atologic malignancies. The use of nonmyeloablative/
educed intensity conditioning (RIC) regimens in recent
ears has increased the applicability of transplantation
o an older population and those with comorbidities
1,2]. The rationale is to reduce toxicity and thus early
ransplant-related mortality (TRM), and although the
onditioning has less activity against the malignancy,
hese protocols exploit the graft-versus-leukemia
GVL) effect [3-5]. Many of these protocols are re-
orted to result in an early state of mixed chimerism
MC), which later may convert to full donor chimerism
FDC), either spontaneously, by reduction/cessation of i
50mmunosuppression (IS) [6], or by donor leukocyte
nfusions (DLI). In the setting of MC, DLI are given
ith an aim to break tolerance and convert the patient
o a state of FDC [7]; however, even in MC, DLI are
ot universally successful. A number of factors have
een reported to be predictive of DLI responsiveness
eg, disease stage and type [8-10], level of chimerism
9,11]); however, parity between studies is not com-
lete.
The achievement of FDC has been shown in some
tudies to be a requirement for the development of
isease control [9,11,12], graft-versus-host disease
GVHD) [13], and improved transplant outcome [14].
he use of DLI in the setting of FDC (for residual
isease or relapse) is reported to be less successful than
n those with MC [15].
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Chimerism and Lymphocytes in Transplantation 551Few studies [16] have been published in recipients
f RIC transplants containing T cell depleting agents
uch as Alemtuzumab. The aim of this retrospective
nalysis was to consider the patterns of chimerism in
uch transplants, and to analyze the impact of chimer-
sm pattern on transplant complications, DLI respon-
iveness, and outcome.
ATERIALS AND METHODS
atients
One hundred twenty-ﬁve patients from a single
ransplant center were included in this retrospective
nalysis. Criteria for inclusion were: patients who re-
eived a transplant using an RIC regimen for a hema-
ologic malignancy, and had results of chimerism anal-
able 1. Patient and Donor Characteristics
Characteristic
Group A
(n  68)
Grou
(n 
atient gender
Male 51 1
onor gender
Male 48 2
atient CMV status
Positive 32 2
Negative 36
onor CMV status
Positive 21 1
Negative 46 1
Unknown 1 —
isease
Chronic myeloid leukemia 3
Acute myeloid leukemia/MDS 19 1
Chronic lymphocytic leukemia 7
Hodgkin’s disease 6
Non-Hodgkin’s lymphoma 23
Multiple myeloma 9
Myelofibrosis 1
Hypereosinophilic syndrome — —
isease stage
Early 20 1
Late 48 1
onditioning regimen
Fludarabine, melphalan, campath 38 1
Fludarabine, busulphan, campath 6
BEAM, campath / fludarabine 21
Other 3
VHD prophylaxis
Cyclosporin alone 43 1
Cyclosporin/methotrexate 22 1
Other 3
Unknown — —
tem cell source
Bone marrow 23
PBSC 45 2
onor
Sibling 29 2
Unrelated 39
MV indicates cytomegalovirus; GVHD, graft-versus-host diseaseses available. The transplants took place between pecember 1997 and March 2005. Patient and donor
haracteristics can be seen in Table 1. The median age
f the patients was 52 years (range: 19-71). The me-
ian age of the donors was 42 years (range: 21-71).
he donors were siblings (68, 55%) or unrelated (57,
5%). The median CD34 cell dose infused was 4.4
06/kg (range: 0.4-18.2  106/kg).
The protocols used were approved by the institu-
ional review board of Nottingham City Hospital.
he appropriate ethical permission was obtained, and
ll patients and donors signed informed consent prior
o transplant/donation.
efinitions
Early-stage disease included those in ﬁrst com-
lete remission (CR) for acute leukemia, ﬁrst chronic
Group C
(n  22)
Group D
(n  8)
Total
(n  125) P Value
.832
17 5 92
.558
14 6 90
.111
13 5 70
9 3 55
.186
9 3 48
13 5 76
— — 1
.459
2 3 10
4 — 33
4 1 16
1 1 10
9 2 40
2 — 13
— — 2
— 1 1
.111
11 4 49
11 4 76
.710
10 3 65
2 2 13
9 3 42
1 — 5
.951
13 4 74
8 3 45
1 — 5
— 1 1
.109
6 5 39
16 3 86
.008
16 3 68
6 5 57
, myelodysplastic syndromes; PBSC, peripheral blood stem cells.p B
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B. E. Shaw et al.552usly untreated myelodysplastic syndrome (MDS),
nd lymphomas in ﬁrst CR or very good partial re-
ission (PR). Human leukocyte antigen (HLA)
atching was considered at 10 alleles (ie, HLA-A,-B,-
,-DRB1,-DQB1). This was high resolution in over
5% of pairs and medium or low resolution in the
emainder. FDC is deﬁned as 99% donor chimer-
sm, MC as between 5% and 99% donor. Chimerism
esponse in those with MC was deﬁned as CR if donor
himerism returned to 99%, and PR if there was
n increase in donor chimerism (without a return to
99%).
onditioning and GVHD Prophylaxis
Conditioning consisted of ﬂudarabine, melphalan,
nd campath (fmc) [17] in 65 patients; ﬂudarabine,
usulphan, and campath [18] in 13 patients; BEAM,
ampath [19]  ﬂudarabine (ﬂudarabine added for
nrelated donor [UD] transplants) (fBEAMc) in 42
atients, and the ﬁnal 5 patients had other regimens (1
ad low-dose total body irradiation (TBI)/ﬂudarabine
FdA) and 4 had ﬂudarabine, cytosine arabinoside, gran-
locyte colony stimulating factor [GCSF] [FLAG]).
ll patients, except those 4 receiving FLAG condi-
ioning and 1 TBI/FdA, had T cell depletion with
lemtuzumab as part of the conditioning regimen
Table 1).
GVHD prophylaxis was with cyclosporine alone
n the majority of patients. This was given at a dose of
mg/kg twice a day, and in the absence of GVHD was
apered from D50 and discontinued at D90. A
roportion of patients, depending on risk, HLA
atching, stem cell and donor source, received meth-
trexate in addition at a dose of 15 mg/m2 on D1
nd 10 mg/m2 on D3, 6 ( D11). Patients re-
eiving FLAG or TBI/FdA conditioning received my-
ophenolate mofetil 15 mg/kg three times daily in
ddition to cyclosporine.
himerism Analyses
Chimerism analysis was performed as described by
iﬂin et al [20]. DNA was extracted from the blood
r bone marrow of donor and/or recipient using the
iagen DNA Blood Mini Kit (Qiagen, Crawley, UK)
nd screened using a panel of ﬂuorescent microsatel-
ite polymerase chain reactions. The products were
nalyzed on an ABI 377 sequencer with Genescan
nalysis software (Applied Biosystems, Foster City,
A). Sequential samples posttransplant were analyzed
ith an informative marker and the percentage of
onor chimerism was calculated from the electro-
herograms [21].
Chimerism was performed on whole blood (ie, not
n fractionated samples), either from peripheral blood
PB) or bone marrow. Samples were analyzed on the
rst bone marrow test posttransplant (performed on jay 28), and thereafter using PB at d100 and then 3
onthly. Those with MC, a change in disease status
eg, relapse), or who had received DLI, had chimerism
nalysis performed 4-6 weeks. This was usually on PB;
owever, any interim bone marrow test was analyzed
or chimerism.
LI
DLI doses varied according to the indication, do-
or source, and time posttransplant, as has been pre-
iously published [22]. Brieﬂy, patients with low level
isease or MC received DLI at 6 months, in incre-
ental doses, starting at 1 106 CD 3 cells/kg. Those
ith progressive disease had 1  106 (UD) or 1  107
siblings) CD 3 cells/kg at 3 months, or 1 log higher
ose, respectively, at 6 months.
DLI was not performed in patients who were still
n immunosuppression or in those who had evidence
f GVHD. Stable MC with predominant donor he-
opoiesis, without evidence of disease, was moni-
ored.
tatistical Analyses
Statistical analysis was performed using SPSS
v.10.0) software (SPSS Inc., Chicago, IL). Associa-
ions were tested using the chi-squared test or Fisher’s
xact test. Time-dependent analyses (overall survival,
hronic GVHD, and disease relapse rates) were ana-
yzed using Kaplan-Meier methods [23], and were
ompared using the log-rank statistic. Multivariate
nalysis of time-dependent variables was performed
sing Cox regression analysis. Patient and donor age
ere grouped for analysis, using the median age as a
utoff. In all univariate analyses the following factors
ere considered: patient and donor age, gender, and
ytomegalovirus (CMV) status, disease and stage at
ransplant, conditioning regimen, GVHD prophy-
axis, stem cell source, and HLA matching status.
atients with raised lymphocyte counts resulting from
isease (eg, chronic lymphocytic leukemia) were ex-
luded from the analysis of pre-DLI lymphocyte
ounts.
ESULTS
attern of Chimerism
The median number of samples assessed for chi-
erism in each patient was 5 (range: 1-30). The me-
ian time to the ﬁrst chimerism analysis was 36 days
range: 14-189). One hundred seven of 125 (86%)
atients were found to have FDC on the ﬁrst occasion
hey were tested. A percentage of patients (12) had
nly 1 test performed at the time of analysis because of
arly death, short follow-up, or primary graft failure
which occurred in 6 of 125 [5%] patients). The ma-
ority of these patients were assigned to group A.
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Chimerism and Lymphocytes in Transplantation 553Following the initial assessment of early chimer-
sm, there were 4 patterns of chimerism that devel-
ped in this cohort, as follows: (A) always 100% DC
68, 54%), (B) persisting MC posttransplant including
ases refractory to withdrawal of immunosuppression
nd DLI (27, 22%), (C) MC posttransplant with sub-
equent development of FDC either on withdrawal of
S or post-DLI (22, 18%), (D) lost DC with autolo-
ous reconstitution (8, 6%). The only pretransplant
ariable to be signiﬁcantly associated with the chimer-
sm pattern was donor type (P  .008). Those with
nrelated donors were signiﬁcantly more likely to fall
nto group A (39 of 57, 68%) than were those with
ibling donors (29 of 68, 43%), whereas more patients
ith sibling donors fell into groups B or C (29% and
4%, respectively) than with unrelated donors (12%
nd 11%, respectively). There was no signiﬁcant as-
ociation with patient or donor age or gender, stem
ell source, CD34 cell dose, conditioning or immuno-
uppressive regimen.
MPACT OF CHIMERISM PATTERN ON TRANSPLANT
OMPLICATIONS AND OUTCOME
urvival
There was a signiﬁcant difference in overall sur-
ival depending on the chimerism pattern P  .009).
hose in group C had a survival advantage at 2 years
ompared to all other groups (95% versus A, 54%; B,
7%; and D, 58%) (Figure 1). This pattern was not
ltered when those with only a single chimerism result
vailable were excluded. In the group overall, there
as a signiﬁcant survival disadvantage between those
eceiving a UD graft compared to 1 from a sibling
3-year survival 41% versus 63%, P  .029). Other
actors signiﬁcantly associated with an improved over-
ll survival (OS) include younger age (P  .019), a
igure 1. Overall survival dependent on chimerism pattern. Group C
8as signiﬁcantly better outcomes.ransplant for lymphoid malignancy or CML com-
ared to myeloma or acute myelogenous leukemia/
DS (P  .017) and BEAM/campath ( ﬂudarabine)
onditioning regimens compared to fmc or FbuC (P
002). There was no difference in survival dependent
n donor age, patient or donor CMV status, HLA
atching status, posttransplant immunosuppres-
ion, or stem cell source. In multivariate analysis the
ost signiﬁcant factor affecting OS was chimerism
attern (with a signiﬁcant survival beneﬁt for pa-
ients in group C (HR 0.054; CI: 0.01, 0.28; P 
001) (Table 2a). There was no signiﬁcant impact
f pre-DLI acute (aGVHD) or chronic GVHD
cGVHD) on OS.
VHD
Forty of 121 (33%) patients developed aGVHD
elated to the transplant procedure, which was grade I
n 29 (24%), grade II in 8 (7%), grade III in 2 (2%),
nd grade IV in 1 patient (1%). The incidence of
GVHD was not signiﬁcantly different dependent on
he chimerism pattern (P .154). In group A, this was
7 of 68, 40% (10  grade I); Group B, 6 of 25, 24%
1 grade I); group C, 7 of 22, 32% (none grade I).
here were no patients with aGVHD in group D.
hose receiving transplants from an unrelated donor
ere signiﬁcantly more likely to develop aGVHD
han those with sibling donors (27 of 54, 50% versus 13
f 67, 19%, P  .0001). This was grade II or greater in
able 2. Multivariate Analysis of Factors
Variable HR 95% CI P Value
. Affecting overall survival
Unrelated donor 0.92 0.31 2.71 .880
Group C 0.05 0.01 0.28 .001
Patient older than 52 2.03 0.73 5.62 .169
CMV positive patient 1.67 0.78 3.57 .183
Lymphoid (constant) — — — —
AML/MDS 1.55 0.49 4.81 .449
CML 0.73 0.18 3.04 .680
Other 0.11 0.00 1.64 .112
MM 1.32 0.29 6.02 .715
FMC conditioning (constant) — — — —
FBuC 5.36 2.04 14.02 .001
BEAMC (/ F) 0.73 0.22 2.41 .608
. Affecting TRM
Unrelated donor 2.14 0.82 5.57 .116
CMV positive patient 2.35 0.97 5.59 .058
Group A (constant) — — — —
Group B 0.13 0.01 1.03 .054
Group C 0.08 0.01 0.68 .021
Group D 0.96 0.25 3.69 .963
FMC conditioning (constant) — — — —
FBuC 2.24 0.65 7.68 .198
BEAMC (/ F) 0.55 0.16 1.81 .328
ML/MDS indicates Acute myelogenous leukemia/myelodysplastic
syndromes; CML, chronic myelogenous leukemia; CMV, cyto-
megalovirus; TRM, transplant-related mortality.(15%) UD transplants and 3 (4%) sibling transplants.
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B. E. Shaw et al.554Overall, 49 of 107 (46%) patients developed
hronic GVHD. In 26 patients (24%) this was not
elated to DLI (patients did not received DLI, or
imited GVHD was present before DLI, n 3). In the
emaining 21 GVHD developed only after DLI (in 2
atients this data is unknown). Considering only pre-
LI cGVHD, the likelihood of developing this com-
lication was highest in group A, compared to all
ther groups (P  .104). In addition, this was signif-
cantly more likely to occur in those with UD (P 
0002).
RM
The overall TRM was 28%. There was a signiﬁ-
ant survival disadvantage at 3 years to those patients
ho fell into groups D (56%) and A (39%), compared
o those in groups B and C (4% and 5%, respectively)
P  .005) (Figure 2). There was also a signiﬁcantly
ncreased TRM in those patients with UD compared
o a sibling donor (P  .002) (Figure 3). Two other
actors showed a trend to increased TRM (condition-
ng other than BEAMc, P  .065 and patient CMV
erostatus positive, P  .097). The presence of
VHD at any stage was not signiﬁcantly associated
ith increased TRM. Interestingly, in mutivariate
nalysis (including factors with a P value .2 in uni-
ariate analysis), the chimerism group was the only
actor to remain signiﬁcantly associated with TRM
Table 2b). No other factors (including patient and
onor age, donor CMV status, HLA matching status,
osttransplant immunosuppression, stem cell source,
r disease) were signiﬁcantly associated with TRM.
To exclude a potential bias produced by an over-
epresentation of patients with a single chimerism
esult in group A, analysis was also done restricted to
hose with durable FDC (2 or more results available).
here remained a signiﬁcantly greater TRM in group
and D compared to C and B (data not shown).
igure 2. TRM dependent on chimerism pattern. Groups C and B
rave a signiﬁcantly lower TRM.isease Relapse
There was a signiﬁcant difference in relapse risk
ependent on chimerism pattern (P  .012). The
owest risk was in group C, with a risk at 2 years of
4%, compared to 37% in group A, 61% in group B,
nd 50% in group D. The type of donor (UD/sibling)
id not have a signiﬁcant impact on relapse risk.
here was no signiﬁcant impact of pre-DLI aGVHD
r cGVHD on relapse risk.
LI
Forty-ﬁve (36%) patients in the group overall re-
eived DLI. The median time to DLI was 197 days
range: 57-2123), and it was used for a number of
ndications (relapse in 15, residual disease in 15, MC
n 14 [associated with relapse in 5], unknown in 1).
he median number of doses of DLI was 1 (range:
-6). The median starting dose was 5  106 CD 3
ells/kg (range: 0.5  105-1.3  108).
In those who received DLI for MC alone, 5 of 9
eturned to FDC, 1 of 9 had no response, and 2 of 9
ere too early post-DLI for analysis. In those receiv-
ng DLI for disease, CR was achieved in 15 of 36
42%), PR in 7 of 36 (19%), and no response in 10 of
6 (28%) (2 cases were too early for formal analysis, 2
nknown).
Neither chimerism nor disease responses to DLI
ere signiﬁcantly associated with the indication for
hich DLI was given, dose of DLI, or the total num-
er of DLI. Nor were donor type, HLA matching
tatus, recipient age, conditioning, stem cell source,
mmunosuppression, and disease type or stage signif-
cantly associated with either response. In addition,
himerism or disease responses were not signiﬁcantly
ssociated with the development of GVHD post-DLI.
wenty-four of 36 (66%) patients developed GVHD
ost-DLI (9 patients were too early for evaluation or
igure 3. TRM dependent on donor type. Those with sibling
onors have a signiﬁcantly lower TRM.esults not known); this was extensive in 50% and
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Chimerism and Lymphocytes in Transplantation 555imited in 50%. All patients with GVHD prior to DLI
7 grade I, 1 grade II) went on to have progressive
VHD post-DLI (limited in 3 and extensive in 5).
LI from a UD was signiﬁcantly more likely to result
n GVHD, particularly in extensive disease (UD: lim-
ted 2 of 11, 18%, extensive 8 of 11, 73% versus
ibling: limited 10 of 25, 40%, extensive, 4 of 25, 16%,
 .004). Interestingly, this was not signiﬁcantly
mpacted upon by the degree of HLA matching. No
ther pretransplant donor, recipient, or regimen-re-
ated factor had an impact on GVHD post-DLI, nor
id the dose, indication, or total number of DLI.
able 3. Indications for and Responses to DLI Therapy
Group pDLI(Ly)* Indication† Dis
A 1.27 Residual disease
A 1.33 Relapse
A 0.56 Residual disease
A 0.22 Relapse
A 1.20 Relapse
A 0.17 Residual disease
A 0.42 Relapse
A 0.37 Relapse
A 1.96 Residual disease
A 1.32 Residual disease
A 0.33 Relapse
A . Residual disease
A 1.46 Relapse
A 0.59 Residual disease
A 1.58 Relapse
A 0.78 Relapse
A 0.48 Relapse
A 1.63 Residual disease
B 2.54 Mixed chimerism
B 2.71 Relapse
B 1.56 Relapse
B 2.09 MC and relapse
B Ex Residual disease
B 0.32 Mixed chimerism
B Ex MC and relapse
B 2.71 Mixed chimerism
B 8.56 Unknown
B 2.88 MC and relapse
B 2.91 Mixed chimerism
C 2.24 Mixed chimerism
C 1.15 Mixed chimerism
C 1.07 Mixed chimerism
C Ex Relapse
C 1.21 Relapse
C 1.31 Mixed chimerism
C Ex Residual disease
C 3.25 Residual disease
C 0.47 Residual disease
C 2.70 Residual disease
C 1.29 Relapse
C 0.74 MC and relapse
C 2.14 MC and relapse
C 0.97 Residual disease
R indicates complete remission; DLI, donor leukocyte infusions;
from this part of the analysis); FDC, full donor chimerism; GVH
lymphocyte counts; PR, partial remission.
Lymphocyte count before the ﬁrst dose of DLI.
Represents the primary indication for DLI therapy (by deﬁnition all thoACTORS ASSOCIATED WITH DLI RESPONSIVENESS
himerism
Patients in groups A and D were least likely to
eceived DLI (18 of 68, 26% and 2 of 8, 25%,
espectively). Overall, 25 patients with MC received
LI, 11 of 27 (41%) in group B and 14 of 22 (64%)
n group C.
The indication for DLI, not surprisingly, did dif-
er between the groups (Table 3); however, the me-
ian time to delivery of DLI was not different (group
 202 days, range 142-862; B  173 days, range
esponse Chimerism Response GVHD Post DLI
— Limited
— Limited
— None
— None
— Unknown
— Limited
— Extensive
— Extensive
— Extensive
— Extensive
— Extensive
— Extensive
wn — Unknown
— None
— Extensive
— None
— Limited
— None
None None
None None
None Limited
PR None
PR Extensive
Too early Too early
arly Too early Too early
Too early Too early
wn Unknown Unknown
arly Too early Too early
Too early Too early
FDC Limited
FDC None
FDC None
FDC Limited
FDC Limited
FDC Extensive
FDC Limited
FDC Limited
FDC Limited
FDC None
FDC Extensive
FDC Extensive
FDC None
FDC Limited
ents with high lymphocyte counts resulting from disease (excluded
ft-versus-host disease; MC, mixed chimerism; pDLI(Ly), pre-DLIease R
PR
CR
None
None
None
PR
CR
CR
None
CR
PR
None
Unkno
None
CR
PR
CR
None
—
None
None
PR
PR
—
Too e
—
Unkno
Too e
—
—
—
—
CR
PR
—
CR
CR
CR
CR
CR
CR
CR
CR
ex, pati
D, grase in groups B and C had MC in addition).
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B. E. Shaw et al.5564-2123; C  214 days, range 57-1674). Only 2 pa-
ients in group D received DLI.
There was also a signiﬁcant difference in the dis-
ase response to DLI between the groups (Table 3).
omplete disease responses were seen in 9 of 10
90%) patients in group C. In contrast, there were
nly 6 of 17 (35%) complete disease responses in
roup A, no complete disease responses in group B,
nd in 1 of 2 patients in group D (P  .027). The
ncidence of GVHD post-DLI also differed between
he groups (although this was not signiﬁcant). GVHD
as most often observed in groups C (10 of 13, 77%)
nd A (11 of 16, 68%), whereas less so in group B (2
f 5, 40%) (P  .430).
The level of pre-DLI chimerism did not have a
igniﬁcant impact on DLI responsiveness or GVHD.
re-DLI Lymphocyte Counts
The median lymphocyte count pre-DLI in all pa-
ients in groups A, B, and C was 1.3  109/L, and
here was a signiﬁcant difference dependent on the
himerism pattern. The lymphocyte count was below
he median in 12 of 17, 71% patients in group A, 1 of
(11%) in group B, and 8 of 12, 67% in group C (P
009) (Table 3).
When only groups B and C patients were consid-
red the difference remained signiﬁcant. The median
ount was 2.09  109/L and in group B 2 of 9 (22%)
ere below this, while 8 of 12 (67%) in group C were
elow this (P  .044).
The pre-DLI lymphocyte count was not signiﬁ-
antly correlated with the time posttransplant at which
LI was given, the use of an unrelated or sibling donor,
he indication for DLI or the disease, conditioning, or
osttransplant immunosuppression regimen.
ISCUSSION
These data show that the chimerism patterns in
ecipients of T cell-depleted (in vivo Alemtuzumab)
IC transplants for hematologic malignancies may
redict overall outcome. Those who developed MC,
ith a subsequent return to FDC, had a superior out-
ome compared to those with sustained MC or FDC.
As has previously been reported, chimerism re-
ponses were strongly associated with disease re-
ponses [9,11,24,25], suggesting that the graft-versus-
alignancy effect and the graft-versus-marrow effect
oexist. It is likely that in responders persisting host
ntigen presenting cells (APCs) were able to contrib-
te to the allogeneic effect. These responses are con-
istent with the notion of “breaking tolerance,” a rec-
gnized phenomenon following T cell-depleted
ransplants [26]. Thus, the remaining host APCs are
ble to present polymorphic peptides to donor T cells,
process shown to be important for a GVL effect bost-DLI [7,24]. Thus, it may be expected that sur-
ival is favorable in this group.
Likewise, the inferior outcome in those with MC
ho fail to respond can be predicted, and indeed,
lmost all the deaths in this group were from recurrent
isease. This ﬁnding is in keeping with recent reports
hat found relapse risk to be higher in patients with
ersisting MC [12,13,25,27,28], and may be under-
tood in the context of data in both murine and human
ransplantation systems showing the development of
mmunotolerance between graft and host in mixed
himaeras, resulting in an impaired GVL effect [6,29].
An unanswered question is what predicts for DLI
esponsiveness. Only 2 factors have thus far been as-
ociated, including underlying disease and levels of
re-DLI chimerism [8-11]. In this study, we found
hat those in the “nonresponding” group had signiﬁ-
antly higher lymphocyte counts pre-DLI than those
ho were “responders.” We discuss a number of po-
ential explanations for this ﬁnding.
First, it is possible that a higher number of circu-
ating lymphocytes limits the amount of “space,” avail-
ble for an appropriate donor alloreactive population
o proliferate in (analogous to the bone marrow
space,” which is required at the time of transplanta-
ion [30]). In a series of elegant experiments in mice,
lazar et al [31] have shown that the ability of T cells
o expand when infused into mice on day 21 posttrans-
lant, was signiﬁcantly lower compared to mice in-
used with T cells on day 0, and that this was associ-
ted with higher numbers of preinfusion residual host
cells present at the later time periods. The mice
xposed to DLI later posttransplant had a reduced risk
f GVHD. Although GVL is not directly analyzed in
hat study, it can be extrapolated from the results of
umerous other studies, in humans, that GVHD and
VL coexist and that common target antigens and
ffector cells are implicated [16,32-34]. In our study,
LI resistance (less GVL and GVHD) was seen in
hose with higher lymphocyte counts.
Second, high numbers of host T cells or particular
ubsets in the residual population of patients with MC
ay also be able to directly reject or suppress incom-
ng donor T cells. The presence (and ability to sup-
ress GVHD responses) of suppressor/regulator cells
of either donor or host origin [35]) has been shown
osttransplant in a number of studies [31,36-38]. This
s borne out in the current study, where the coexist-
nce of persistent host cells with high numbers of
ymphocytes is associated with DLI resistance. Addi-
ional evidence from a recent study is that ex vivo
xpanded Treg cells have been shown in vivo (in dogs)
o restore tolerance mechanisms broken by low dose
BI and DLI [39].
There are other potential reasons for the differ-
nce between the 2 groups. It is important to remem-
er that although the results obtained thus far are
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Chimerism and Lymphocytes in Transplantation 557ompelling, because of the heterogeneity of the co-
ort (in terms of disease, conditioning, indications for,
nd types of intervention) these observations must be
egarded as preliminary. It is possible that other asso-
iations, although sought, may have been hidden.
ther factors to consider are that the tempo of relapse
nd MC development differs according to the under-
ying disease, and that the numbers in this study were
nsufﬁcient to uncover this factor. Some tumors may
imply develop too rapidly to be controlled by an
mmune response [40]. In addition, because of the lack
f lineage speciﬁc chimerism in this study, the effect
PCs cannot be proved. It is possible that host signals
ay be derived from other hematologic or even ma-
ignant cells.
Previously (although not in this study) it has been
hown that low levels of donor T cell chimerism
usually 40%) are associated with poor responses to
LI [9,11,24]. In the setting of low chimerism, it has
een suggested that lymphocyte depleting agents,
uch as pentostatin, may be beneﬁcial to promote DLI
esponsiveness, and early data supports this hypothesis
41]. It is possible that a similar approach involving
ymphoreduction pre-DLI may be beneﬁcial in patients
uch as those in group B in this study; however, conﬁr-
ation of this ﬁnding in other studies is required.
As has been reported [16,24], we were unable to
how that the presence of sustained FDC protected
gainst relapse or predicted the best outcome even in
hose who did not relapse. In addition, the responses
o DLI in this group were intermediate. One possible
xplanation for the responsiveness of a proportion of
atients in this subgroup to DLI is that whole blood
himerism (used in our study) may not adequately
eﬂect subset chimerism. It is possible that patients
ho responded to DLI had low-level MC only in
ertain subsets, which was not detected in our chimer-
sm assay. Alternative approaches are clearly indicated
n this subgroup. In mice, it has been shown that
eﬁcient GVL reactivity can be partially restored in
DC by the coinfusion of host-type DCs and DLI;
owever, an increase in GVHD is also noted [35]. A
urther consideration is that patients with unrelated
onors were more likely to be found in group A, and
hus the inferior survival and higher TRM in this
roup is likely to have been contributed to by this fact.
nterestingly, the use of UDs was not a signiﬁcant
actor in the multivariate analysis. However, it is pos-
ible that additional factors in such transplants may
ave contributed to the poorer outcomes (eg, higher
mounts, or longer duration of immunosuppressive
reatment associated with a higher incidence of
VHD). The majority of nonrelapse deaths resulted
rom infection. This subgroup of patients would ben-
ﬁt from further study.
Further studies in humans are required in an at-
empt to elucidate these mechanisms. The analysis ofhimerism in multilineage subsets will be crucial to
etter our understanding, with particular reference to
he donor or recipient origin of recovering lympho-
ytes and their phenotype. This may be particularly
elevant in the development of strategies to improve
he outcomes in group A patients.
In conclusion, we have shown results that suggest
n improved survival in patients with MC posttrans-
lant, who later achieve FDC. We have shown DLI
esponsiveness in this setting to be related to the
resence of reduced lymphocyte counts preinfusion.
lthough these results are compelling, in view of the
eterogeneity of the patients studied in terms of dis-
ase, protocols, and interventions, these results should
e viewed as preliminary, and will require conﬁrma-
ion in a larger and more cohesive cohort of patients.
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